

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	HMC Capital Limited (ASX: HMC)
ABN	94 138 990 593

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Christopher Roberts
Date of last notice	21 February 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect interest
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<ul style="list-style-type: none"> Romaxis Pty Ltd (ACN 126 199 924) as trustee for <Roblis Super Fund A/C> (of which Christopher Roberts is a beneficiary) (Romaxis) Acemed Pty Ltd (ACN 078 477 193) as trustee for <MAXIS A/C> (of which Christopher Roberts is a beneficiary) (Acemed)
Date of change	<ul style="list-style-type: none"> 9 April 2025 in relation to the acquisition by Romaxis 8 April 2025 in relation to the acquisition by Acemed

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

No. of securities held prior to change	<p>Direct interest:</p> <ul style="list-style-type: none"> 714 fully paid ordinary shares 3,952 rights to acquire fully paid ordinary shares <p>Indirect interest:</p> <ul style="list-style-type: none"> Romaxis – 83,188 fully paid ordinary shares Acemed – 63,188 fully paid ordinary shares and 10,000 options (exercise price of \$7, expiry 30/11/25).
Class	Fully paid ordinary shares
Number acquired	<ul style="list-style-type: none"> 66,812 fully paid ordinary shares acquired by Romaxis 86,812 fully paid ordinary shares acquired by Acemed
Number disposed	Nil
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<ul style="list-style-type: none"> \$4.66 per fully paid ordinary share in relation to the acquisition by Romaxis \$4.73 per fully paid ordinary share in relation to the acquisition by Acemed
No. of securities held after change	<p>Direct interest:</p> <ul style="list-style-type: none"> 714 fully paid ordinary shares 3,952 rights to acquire fully paid ordinary shares <p>Indirect interest:</p> <ul style="list-style-type: none"> Romaxis – 150,000 fully paid ordinary shares Acemed – 150,000 fully paid ordinary shares and 10,000 options (exercise price of \$7, expiry 30/11/25).
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	Acquisition of fully paid ordinary shares on market.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Not applicable
---------------------------	----------------

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No.
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

+ See chapter 19 for defined terms.